---
title: "prechemo_TNBC"
slug: "prechemotnbc"
date: "2024-02-04"
prefix: "prechemo_TNBC"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ªï¼š[[Chart template-of-breast cancer]]

# prechemo_TNBC

< Diagnostic >

- for recurrence early stage TNBC, consider CT scan for chest, abdomen, and pelvis
- consider PET-CT

< Theraputic >

- arranged Por-A implentation
- Cyle 1-4 (Cycled every 3 weeks)
  - Doxorubicin 60 mg/m2, Cyclophosphamide 600 mg/m2
  - Pembrolizumab 200 mg (out-of-pocket expense $65,226NTD x 2 vial x 4 = 521,808)
- Cycle 5-8 (Cycled every 3 weeks)
  - Docetaxel\* 60 mg/m2
  - Pembrolizumab 200 mg (out-of-pocket expense $65,226NTD x 2 vial x 4 = 521,808)
- then proceed to surgery
- post-op XRT if indicated

< Education >

- explained reason of < adjuvant / neoadjuvant > chemotherapy: achieve pathological complete response (pCR), to cure and lower the risk of recurrence/metastasis.
- explained chemotherapy schedule
- explained potential chemotherapy toxicities:
  - <> cyclophosphamide: bone marrow function compromised, hemorrhagic cystitis
  - <> doxorubicin: cardiotoxicity, with life-time culmucation 450-500 mg/BSA (300mg/BSA this course)
  - <> docetaxel: stomatitis, persistent febrile neutropenia, cutaneous reactions, moderate neurosensory effects
- explained potential ICI toxicities:
  - pembrolizumab: skin rash pneumonitis, colitis, hepatitis, hypophysitis, thyroid dysfunction, diabetes mellitus
- suggested high protein diet, not suggested chicken essence because it may confound the lab.
